We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Erbitux sBLA for Cancer Indication Withdrawn From the FDA
Erbitux sBLA for Cancer Indication Withdrawn From the FDA
January 30, 2009
Erbitux, the cancer drug at the heart of the collaboration between Bristol-Myers Squibb and ImClone, has suffered a setback with the companies’ withdrawal of the sBLA for an additional indication to treat advanced nonsmall cell lung cancer (NSCLC).